Document is current

Article History

Received: 7 April 2025

Accepted: 9 October 2025

First Online: 24 November 2025

Declarations

:

: The work was supported by research funding to CN from the Swedish Research Council for Health, Working Life and Welfare, The Crafoord Foundation, and Magnus Bergvalls Foundation, to KN from the Southern health care region, Sweden, the S.R. Gorthon foundation, the Welander Finsen foundation (Hudfonden), the LMK foundation, grants from the Swedish state under the agreement between the Swedish government and the county councils (the ALF agreement), the Inga and John Hain Foundation for medical research, and the Gyllenstiernska Krapperup Foundation. KN has received speaker honoraria from Galderma Sweden, LEO Pharma Sweden, Novartis Sweden and UCB Pharma Sweden. KN has 2021 served on one advisory board for Merck Sharp and Dohme (MSD), and finally KN is President of the Board for the National Melanoma Guidelines and President for the Swedish Society of Dermatological Surgery and Oncology. The authors declare no other relationships or activities that could appear to have influenced the submitted work.

: The study was approved by the Swedish Ethical Review Authority (no. 2019–03138). Participants consented to participation by answering the questionnaire. The study was performed in accordance with the Declaration of Helsinki.

: No personal data was published on an individual level in this study.